U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Showing 1 - 3 of 3 results

Status:
US Approved Rx (2024)
First approved in 2022

Class (Stereo):
CHEMICAL (ACHIRAL)



Vonoprazan (Vonoprazan fumarate or TAK-438) under brand name Takecab, discovered by Takeda, is a new medicine for treating acid-related diseases with a novel mechanism of action called potassium-competitive acid blockers (P-CABs) which competitively ...
Status:
Possibly Marketed Outside US

Class (Stereo):
CHEMICAL (RACEMIC)



Osutidine (T-593) is a H2 receptor antagonist which was undergoing development by Toyama Chemical for the treatment of peptic/gastric and duodenal ulcers. It is a beta-hydroxyphenethylamine derivative with both antisecretory and cytoprotective proper...
Status:
US Approved Rx (2024)
First approved in 2022

Class (Stereo):
CHEMICAL (ACHIRAL)



Vonoprazan (Vonoprazan fumarate or TAK-438) under brand name Takecab, discovered by Takeda, is a new medicine for treating acid-related diseases with a novel mechanism of action called potassium-competitive acid blockers (P-CABs) which competitively ...